This randomized, multicenter, double-blind, placebo-controlled, parallel-group s tudy will evaluate the efficacy and safety of lebrikizumab in patients with idio pathic pulmonary fibrosis. Patients will be randomized to receive either lebriki zumab or placebo subcutaneously (SC) every 4 weeks.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.